{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:59:27Z","timestamp":1780775967854,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejso.2024.107967","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T11:44:11Z","timestamp":1704887051000},"page":"107967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2890","authenticated-orcid":false,"given":"Francisco Pimentel","family":"Cavalcante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-727X","authenticated-orcid":false,"given":"Felipe Pereira","family":"Zerwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-7076","authenticated-orcid":false,"given":"Alessandra Borba Anton","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-2011","authenticated-orcid":false,"given":"Patr\u00edcia Klarmann","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryane","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-623X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-6324","authenticated-orcid":false,"given":"Eduardo Camargo","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-6898","authenticated-orcid":false,"given":"Antonio Luiz","family":"Frasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejso.2024.107967_bib1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.107967_bib2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A\u00a0randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2024.107967_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ejso.2024.107967_bib4","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","article-title":"Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review","volume":"45","author":"van Deurzen","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2024.107967_bib5","first-page":"18","article-title":"Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: initially node negative and node positive converted to node negative. A systemic review and meta-analysis","volume":"24","author":"Shirzadi","year":"2019","journal-title":"J\u00a0Res Med Sci"},{"issue":"5","key":"10.1016\/j.ejso.2024.107967_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.acra.2009.01.026","article-title":"Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta-analysis","volume":"16","author":"Kelly","year":"2009","journal-title":"Acad Radiol"},{"issue":"14","key":"10.1016\/j.ejso.2024.107967_bib7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejso.2024.107967_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.107967_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2024.107967_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2024.107967_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.107967_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.107967_bib13","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2024.107967_bib14","article-title":"Challenges in the journey of breast cancer patients in Brazil","volume":"16","author":"Buzaid","year":"2020","journal-title":"Brazilian Journal of Oncology"},{"issue":"1","key":"10.1016\/j.ejso.2024.107967_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/cco-22-110","article-title":"Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice","volume":"12","author":"Cavalcante","year":"2023","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.107967_bib16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.ejso.2024.107967_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","article-title":"Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)","volume":"261","author":"Boughey","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2024.107967_bib18","article-title":"Changes in surgical management of the axilla over 11 years: report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial","author":"Boughey","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2024.107967_bib19","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.107967_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.107967_bib21","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.107967_bib22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2024.107967_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"25","key":"10.1016\/j.ejso.2024.107967_bib24","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"OlympiA clinical trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2024.107967_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ejso.2024.107967_bib26","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2024.107967_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JGO.19.00351","article-title":"Role of axillary surgery after neoadjuvant chemotherapy","volume":"6","author":"Cavalcante","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2024.107967_bib28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.ejso.2024.107967_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/tbj.12793","article-title":"Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy?","volume":"23","author":"Kantor","year":"2017","journal-title":"Breast J"},{"key":"10.1016\/j.ejso.2024.107967_bib30","first-page":"1357","article-title":"Management of the positive sentinel lymph node following neoadjuvant chemotherapy: results of a survey conducted with breast surgeons","volume":"16","author":"Cavalcante","year":"2022","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"10.1016\/j.ejso.2024.107967_bib31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:20:56Z","timestamp":1780773656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0748798324000192"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.107967","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.107967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107967"}}